ALKERMES | ALKS - Operating Expenses

Stock Price
33.31
Daily Change
-0.60 -1.77%
Monthly
13.42%
Yearly
19.65%
Q2 Forecast
32.32

ALKERMES reported $326.44M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Otsuka Holdings JPY 582.9B 113.74B Dec/2025
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025